Central Manchester Hospitals support MSP acquisition of Alderley Park
The new owners of Alderley Park shared their vision for the
future of AstraZeneca's former R&D site at the celebratory
launch event on 9th May 2014 held at the Cheshire site. Manchester
Science Parks (MSP) shareholders were joined by local, regional and
national business and community leaders.
Manchester Science Parks, who with majority shareholder
Bruntwood acquired the 400 acre site in March, revealed its
ambition to maintain top quality bioscience as the cornerstone of
its commercial strategy. MSP praised the investment record of
previous owners AstraZeneca, and set out how the state-of-the-art
research facilities at the site will be adapted to a new
business model, where a vibrant community of businesses would
specialise in different aspects of the drug discovery chain,
working in a campus environment to encourage collaboration and the
sharing of risk.
MSP, which with property partner Bruntwood, has a long track
record of creating inspiring places for business success, also
shared its vision for the 400 acre site in the heart of the
Cheshire countryside. The new owner emphasised the importance of
putting people at the heart of the Park, and of creating a place of
beauty which nurtures creativity and helps businesses balance the
pressures of working life with the promotion of well-being,
leisure, and pleasure.
Chris Oglesby, Bruntwood CEO and MSP Chairman, said:
"Through our acquisition of Alderley Park, we have a unique
opportunity to create a diverse innovative community of bioscience
businesses which is internationally respected for the quality of
its work and as a sustainable business model. With our partners and
the community of exceptional scientists who choose to remain at the
Park, we will build a flagship for a vibrant life sciences industry
in the North of England"
The vision for Alderley Park to remain at the forefront of
bioscience innovation is supported by MSP's public sector and
academic partners, including the two Manchester universities,
Manchester, Salford and Cheshire East Councils, and the Central
Manchester University Hospitals NHS Foundation Trust. All partners
are united in working together to develop a bioscience business
cluster at the site that could establish Alderley Park as an
internationally recognised centre of scientific excellence at the
heart of the North West.
Professor Dame Nancy Rothwell, President and Vice Chancellor,
The University of Manchester, commented:
"I am delighted to see the progress that has been made in
ensuring the future of Alderley Park as a site of outstanding
science. This has been achieved through excellent collaboration
between the partners who are here today."
Former owners of the site, AstraZeneca, will continue to have a
long-term presence at Alderley Park, with over 700 employees
retained on site, and will assist MSP in delivering its vision by
supporting start-up and growing smaller life science businesses.
AstraZeneca is committed to ensuring its legacy continues and has
pledged a £5m contribution to the 'Alderley Park Springboard Fund'
that will be used to support new businesses starting up at Alderley
Park. MSP will also contribute £5m to the new Fund, and is
optimistic that further contributions will ensure that it can play
an important role in retaining and nurturing talent and enterprise
at Alderley Park.
Mene Pangalos, Executive Vice President Innovative Medicines and
Early Development, AstraZeneca, stated:
"As we handover ownership of Alderley Park, we can look
back with pride on the important role the site has played in our
success. We are delighted that our legacy of scientific
innovation stretching back many decades will be built upon by
Manchester Science Parks, helping ensure the UK remains a
global leader in life sciences."
The launch event provided an opportunity for attendees to gain
an insight into the discussions around the exciting vision for the
future of Alderley Park. Chaired by Chris Oglesby, Bruntwood CEO
and MSP Chairman, the event brought together a high profile
delegation of representatives from MSP, Bruntwood, The University
of Manchester, Cheshire East Council and AstraZeneca, including the
Right Honourable George Osborne MP as keynote speaker.
As Chancellor of the Exchequer and the local Member of
Parliament for Tatton, Mr Osborne explained the Government's
commitment to Alderley Park and the importance of securing the
future of the site. The new state-of-the-art science hub will form
an integral part of an ambitious global Life Science Strategy for
the UK, as well as act as a driver for a single health science
strategy for the North West region and beyond.
At the launch event, Mr Obsorne presided over the handing over
of Alderley Park from Mene Pangalos, Executive Vice President
Innovative Medicines and Early Development at AstraZeneca to Chris
Oglesby, Bruntwood CEO and MSP Chairman. This symbolic event marks
the start of the transformation of Alderley Park by its new owners,
Manchester Science Parks.
Notes to Editors
About Manchester Science Parks
A Greater Manchester based public-private partnership and
science park operator, MSP has over 30 years' experience in
creating the right environments for innovation. MSP has a track
record of supporting the growth of companies in the biomedical,
ICT, industrial technologies and digital media sectors, ranging in
size from start-ups to international centres of R&D excellence.
MSP's shareholders are Bruntwood Ltd, The University of
Manchester, Manchester Metropolitan University, and Manchester and
Salford City councils. The acquisition is funded by Bruntwood, MSP
and Cheshire East Council, with Bruntwood as the majority funder.
For more information, please visit: www.manchesterscienceparks.co.uk
Bruntwood is a family-owned and run property company whose goal
is to create the right places for businesses to succeed. With over
109 office buildings across Manchester, Liverpool, Leeds and
Birmingham, Bruntwood specialises in providing bespoke workspace
from one desk for a day through to a whole building for 25 years.
Over the company's 36-year history they have developed a proven
business model that is based on the innovative development of
commercial buildings combined with a single-minded focus on the
needs of their customers. In 2012, Bruntwood applied this model to
Manchester Science Parks (MSP) when they took a majority share in
the site. Each year Bruntwood and the Oglesby family shareholders
donate a figure in excess of 10% of profits to art and charity
initiatives that make a difference to the cities they operate in.
For further information, please visit: bruntwood.co.uk
AstraZeneca is a global, innovation-driven biopharmaceutical
business that focuses on the discovery, development and
commercialisation of prescription medicines, primarily for the
treatment of cardiovascular, metabolic, respiratory, inflammation,
autoimmune, oncology, infection and neuroscience diseases.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more
information, please visit: www.astrazeneca.com
For media enquiries please contact:
T: 0161 711 0305 / 07921000775